Increase the quantity and viability of the stem cells, in the umbilical cord blood samples in pregnant women supplemented with DHA. Pregnancy and Childbirth
Conditions
Interventions
150 pregnant women will be recruited from the Gynaecological and Obstetrics Service of the ?San Giovanni Calibita FatebeneFratelli-Roma hospital, and from the SmartBank?s clients. ?Each participant re
oxidant impurities, dioxins and furans, dioxin-type polychlorinated biphenyls, polycyclic aromatic hydrocarbons). The packaging of the capsules in the two groups is identical. Additionally, all partic
Sponsors
SmartBank (Italy)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Age >18 years 2. Absence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the absence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus).
Exclusion criteria
Exclusion criteria: 1. Age <18 years 2. Presence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the presence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus). 3. Cord blood samples with a volume of less than 80 ml and/or less than 70% cell vitality are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of the viability (%) and the number of CD34+ cells collected from the umbilical cord blood at birth from the patients treated with placebo or DHA from the 20th or from the 28th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| Understand which stage of the supplementation with DHA (the second or the third trimester of pregnancy) is more effective in terms of quantity and viability of the stem cells, in the umbilical cord blood samples. | — |
Countries
Italy
Outcome results
None listed